Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.
- Second complete response in BTKi combination cohort
- First Mantle Cell Lymphoma patient achieves remission post-BTKi failure
- Azer-cel offers off-the-shelf CAR T therapy advantage
- Trial ongoing across US and Australian sites
- BTKi market valued at US$12 billion with resistance challenges
Breakthrough Response in Hard-to-Treat Lymphoma
Imugene Limited (ASX:IMU) has scored a notable milestone in its Phase 1b azer-cel trial, reporting a complete response (CR) in its first Mantle Cell Lymphoma (MCL) patient treated with a concurrent Bruton Tyrosine Kinase inhibitor (BTKi). This patient had previously failed BTKi therapy, a scenario that typically leaves few treatment options due to the development of resistance.
MCL is a notoriously aggressive and incurable B-cell non-Hodgkin lymphoma at advanced stages. BTKi therapies, while standard, eventually lose efficacy for many patients as resistance or intolerance emerges. Imugene’s ability to induce a CR in this challenging cohort underscores the potential of azer-cel combined with BTKi to address a significant unmet medical need.
Azer-cel’s Off-the-Shelf CAR T Advantage
Azer-cel (azercabtagene zapreleucel) is an allogeneic CAR T cell therapy targeting CD19, designed to treat blood cancers with a rapid turnaround time. Unlike autologous CAR T therapies that require weeks for manufacturing from the patient’s own cells, azer-cel is derived from healthy donors and ready for administration within days. This off-the-shelf approach could transform treatment accessibility and timelines.
So far, four patients have been dosed in the BTKi combination cohort, with two evaluable patients, both achieving complete responses. This early efficacy, alongside a manageable safety profile, bolsters confidence in the concurrent dosing strategy. Patient enrolment continues across ten US and five Australian sites, broadening the dataset and clinical insights.
Tapping into a Large and Growing Market
The global BTKi market is valued at approximately US$12 billion, driven by widespread use in B-cell malignancies such as MCL, follicular lymphoma, and chronic lymphocytic leukemia. However, resistance remains a major hurdle, leaving a substantial patient population with limited options after BTKi failure.
Imugene’s concurrent BTKi cohort aims to restore or enhance therapeutic responses by combining azer-cel with BTKi therapy. This approach could carve out a significant clinical and commercial opportunity if further data confirms durable responses and safety.
Next Steps and Market Implications
Managing Director Leslie Chong highlighted the importance of this second complete response in the cohort, particularly in the first MCL patient treated, as a strong signal of azer-cel’s potential. The company plans to update the market as additional patient data matures, which will be critical to assessing the therapy’s broader applicability and commercial viability.
With the trial still in early phases and patient numbers limited, the real test lies ahead in sustaining these responses and expanding the therapy’s reach. The ongoing enrolment across multiple sites in the US and Australia will provide a clearer picture of azer-cel’s role in BTKi-resistant blood cancers.
Bottom Line?
Azer-cel’s emerging efficacy in BTKi-resistant lymphoma patients marks a promising step, but longer-term data will be pivotal to defining its clinical and commercial impact.
Questions in the middle?
- Will azer-cel maintain durable responses in a larger BTKi-resistant patient population?
- How will azer-cel’s safety and tolerability profile evolve with more patients treated?
- What regulatory pathways will Imugene pursue to accelerate azer-cel’s market approval?